Iwanka Kozarewa - Concepedia

Author

Iwanka Kozarewa

Institute of Cancer Research

Also Known As

A. Gajjar, G. Neale, I Kozarewa, I. Kozarewa, Iwanka Kozarewa, Kozarewa, I, L. Bjerke, S Jugurnauth-Little

103

Publications

8.9K

Citations

H-Index

Concepts

All Affiliations

Institute of Cancer Research Breast Cancer Now AstraZeneca (United Kingdom)Royal Marsden NHS Foundation Trust Wellcome Sanger Institute

About

Iwanka Kozarewa is an author at Institute of Cancer Research specializing in medicine, pathology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	22	4.6K
2	Engineering	9	9	1.6K
3	Health Sciences	4	4	1.4K
4	Natural Sciences	2	2	254
5	Public Health	1	1	54

Iwanka Kozarewa

Publications

7.2K

Citations

H-Index

Page 1

	Year	Citations
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer Isaac García-Murillas, Gaia Schiavon, Britta Weigelt, Science Translational Medicine Breast OncologyCancer PathologyPathologyTumor BiologyOncology	2015	1.1K
A large genome center's improvements to the Illumina sequencing system Michael A. Quail, Iwanka Kozarewa, Frances J.D. Smith, Nature Methods BioinformaticsBiologyLarge Genome CenterLong-read SequencingFunctional Genomics	2008	728
Amplification-free Illumina sequencing-library preparation facilitates improved mapping and assembly of (G+C)-biased genomes Iwanka Kozarewa, Zemin Ning, Michael A. Quail, Nature Methods Long-read SequencingSequencingFunctional GenomicsNext-generation SequencingGenetics	2009	576
Analysis of <i>ESR1</i> mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer Gaia Schiavon, Sarah Hrebien, Isaac García-Murillas, Science Translational Medicine	2015	540
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study Susan M. Domchek, Sophie Postel‐Vinay, Seock‐Ah Im, The Lancet Oncology Phase 1/2Breast OncologyOncologyBasket StudyPathology	2020	435
Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity Ilirjana Bajrami, Jessica Frankum, Asha Konde, Cancer Research EngineeringMolecular BiologyPathologySmall-molecule InhibitorsGene Characterization	2013	361
Secondary mutations in <i><scp>BRCA2</scp></i> associated with clinical resistance to a <scp>PARP</scp> inhibitor Louise J. Barber, Shahneen Sandhu, Lina Chen, The Journal of Pathology EngineeringGeneticsPathologyMolecular GeneticsTreatment Resistance	2012	334
Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C Nicola H. Dryden, Laura R. Broome, Frank Dudbridge, Genome Research	2014	263
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma Brian A. Walker, Christopher P. Wardell, Lorenzo Melchor, Blood	2012	242
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial Jeeyun Lee, Seung Tae Kim, Kyung Kim, Cancer Discovery	2019	222

Page 1